RxDoctor Payments Data

Robert Paul, DO

Family Medicine · Benbrook, TXNPI 1902858566

Payments from drug & device makers

$10,970in general payments, 2019–2025

Across 631 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Lilly USA, LLC$1K
  • Novo Nordisk$930
  • Boehringer Ingelheim$769
  • AbbVie$675
  • Pfizer$608
  • plus $5K from 44 others

What the payments were for

  • Food & beverage$10,941100%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,970 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$99,495
Medicare patients
437
Services billed
1,760

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin118$137,806
EliquisApixaban118$123,923
TrulicityDulaglutide60$105,724
FarxigaDapagliflozin Propanediol62$76,948
OzempicSemaglutide43$76,763
MounjaroTirzepatide51$59,043
RybelsusSemaglutide32$44,489
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$37,813
JanuviaSitagliptin Phosphate29$34,498
CreonLipase/Protease/Amylase12$27,875
Breztri AerosphereBudesonide/Glycopyr/Formoterol34$24,012
MyrbetriqMirabegron17$17,873
XareltoRivaroxaban13$16,449
Repatha SureclickEvolocumab16$10,795
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$8,484

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$1,089$164,768111 claims
Boehringer IngelheimJardiance, Spiriva Respimat$769$145,224132 claims
PfizerEliquis$608$123,923118 claims
Novo NordiskOzempic, Rybelsus$930$121,25275 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,842$100,96096 claims
GSKTrelegy Ellipta$481$37,81337 claims
MerckJanuvia$186$34,49829 claims
AbbVieCreon$675$27,87512 claims
Astellas Pharma US IncMyrbetriq$394$17,87317 claims
Johnson & JohnsonXarelto$98$16,44913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Benbrook

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →